Mais les résultats doivent être attendus longtemps et il n'y a généralement pas de temps azithromycine prix L'autre cas, c'est que l'achat d'un ou d'un autre antibiotique dans une pharmacie classique nécessite des dépenses matérielles considérables et pas toutes les personnes ne peuvent acheter des produits pharmaceutiques aussi coûteux.
The New York Times
The Diabetes Dilemma for Statin Users
By ERIC J. TOPOL
We’re overdosing onlowering statins, and the consequence could be a
This past week, the Food and Drug Administration raised questions about the side
effects of these drugs and developed new labels for these medications that wil now
warn of the risk ofand The announcement said the risk was
“smal ” and should not material y affect the use of these medications. The data are
somewhat ambiguous for memory loss. But the magnitude of the problem for diabetes
becomes much more apparent with careful examination of the data from large clinical
have been available since the 1980s but their risk of inducing diabetes did not
surface for nearly 20 years. When al the data available from multiple studies was pooled
in 2010 for more than 91,000 patients randomly assigned to be treated with a statin or a
sugar pil (placebo), the risk of developing diabetes with any statin was one in every 255
patients treated. But this figure is misleading since it includes weaker statins like
Pravachol and Mevacor — which were introduced earlier and do not carry any clear-cut
risk. It is only with the more potent statins (now known as simvastatin),
(atorvastatin) and(rosuvastatin) — particularly at higher doses, that the risk of
diabetes shows up. The cause and effect was unequivocal because the multiple large
trials of the more potent statins had a consistent excess of diabetes.
For those statins, the higher the dose, the more diabetes, though we don’t have enough
data yet to say with precision at which dose excess diabetes showed up for each drug.
What we do know is that diabetes showed up. The numbers increase to one in 167 for
patients taking 20 mil igrams of Crestor, and up to one in 125 for intensive statin
treatments involving drug strategies to markedly lower cholesterol levels. Let’s just round
this off and say that one in every 200 patients treated with any of the three most potent
statins will get the side effect of diabetes. That’s quite a conservative number because
diabetes was not even being careful y looked for in most of the trials. And we have data
for only 5 years of treatment; it might be worse with longer statin therapy.
More than 20 mil ion Americans take statins. That would equate to 100,000 new statin-
induced diabetics. Not a good thing for the public health and certainly not good for the
individual affected with a new serious chronic il ness.
If there were a major suppression of heart attacks or strokes or deaths, that might be
justified. But in patients who have never had heart disease and are taking statins to
lower their risk (so-cal ed primary prevention), the reduction of heart attacks and other
major events is only 2 per 100. And we don’t know who the 2 per 100 patients are who
benefit or the one per 200 who wil get diabetes! Moreover, the margin of benefit to risk
What should people who are taking statins do? If they are prescribed for someone who
has already had heart disease or a stroke, the benefit is overriding — no changes are
suggested. But in the vast majority of people who take statins — those who have never
had any heart disease — there should be a careful review of whether the statin is
necessary, in light of the risk of diabetes and the relatively smal benefit that can be
derived. Beyond that, a dose reduction or use of a less potent statin should be
We need to find out why statins cause diabetes and, ideal y, through genomics we could
determine who is at risk for this important side effect. But to date nothing has been done
to sort this out — despite the fact that the market for statins is wel over $20 bil ion per
year. There are thousands of blood samples sitting in company freezers around the
world that could potential y provide the answers.
The announcement, medication label change and health advisory by the F.D.A. were
long overdue, and have brought this important public health issue to light. The
information that we have does not support that this is a “smal ” problem unless one
considers more than 100,000 new diabetics insignificant. The problem of statin-induced
diabetes cannot be underplayed while the country is being overdosed.
is a cardiologist at the Scripps Clinic, a professor of genomics at the
Scripps Research Institute and the author of “The Creative Destruction of Medicine.”
EARN CATEGORY I CME CREDIT by reading this article and the article beginning on page 40 and successfully completing the posttest on page 45. Successful completion is defined as a cumulative score of at least 70% correct. This material has been reviewed and is approved for 1 hour of clinical Category I (Preapproved) CME credit by the AAPA. The term of approval is for 1 year from the publicati
The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of thisannouncement, makes no representation as to its accuracy or completeness and expressly disclaimsany liability whatsoever for any loss howsoever arising from or in reliance upon the whole or anypart of the contents of this announcement. GREATERCHINA TECHNOLOGY GROUP LIMITED (incorporated in the Cayman Isla